Trevi advances Haduvio to Phase 3 for IPF cough, raises $288M, extends runway to 2030

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Phase 2b CORAL trial met primary endpoint with 60% cough reduction at highest dose vs 17% placebo; FDA aligned on two Phase 3 trials starting Q2 2026, topline data expected 2H 2027 and 1H 2028

  MD&A: Phase 2b CORAL results and Phase 3 design verify on EDGAR →
• high

  Raised $288M across two offerings (June 2025 at $5.75/share, April 2026 at $13.00/share); cash runway extended from Q4 2026 to 2030, funding IPF Phase 3 through potential FDA approval

  MD&A: Capital raises and cash runway verify on EDGAR →
• high

  Expanded pipeline with Phase 2b trials planned for non-IPF ILD (2H 2026) and refractory chronic cough (Q2 2026), both with topline data expected 2H 2027

  MD&A: Non-IPF ILD and RCC programs verify on EDGAR →